Professor Dr. Jens Ellrich has been named the new chief scientific officer at Dopavision, a clinical-stage company pioneering the development of digitally delivered light-based therapeutics. Dr. Ellrich brings a wealth of scientific knowledge and extensive experience in digital therapeutics, including new product development. He will spearhead Dopavision’s ambitious research and development activities for the company’s lead product, MyopiaX, Dopavision’s leading-edge digital therapeutic for childhood myopia control. The first-in-human clinical investigation of MyopiaX is ongoing across Europe. Jens Ellrich, MD, PhD, is an expert in translational medicine with a strong background and track record in basic and clinical neurosciences, including various eye diseases and the development of digital therapeutics. Read More